Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models. METHODS: -mutant NSCLC. Three cohorts were defined according to previous therapy: cohort D comprised previously treated patients who had not received HER2-targeted therapy; cohort E, patients who had previously received HER2-directed antibody-drug conjugates; and cohort F, patients who had not previously received treatment. The primary end point was an objective response, as assessed by blinded independent central review. Secondary end points were duration of response and progression-free survival. RESULTS: A total of 209 patients received sevabertinib (as of June 27, 2025, the data-cutoff date); the median duration of follow-up was 13.8 months in cohort D, 11.7 months in cohort E, and 9.9 months in cohort F. Among 81 patients in cohort D, an objective response was observed in 64% (95% confidence interval [CI], 53 to 75); the median duration of response was 9.2 months (95% CI, 6.3 to 13.5), and the median progression-free survival was 8.3 months (95% CI, 6.9 to 12.3). Among 55 patients in cohort E, an objective response was observed in 38% (95% CI, 25 to 52); the median duration of response was 8.5 months, and the median progression-free survival was 5.5 months. Among 73 patients in cohort F, an objective response was observed in 71% (95% CI, 59 to 81), and the median duration of response was 11.0 months; data on progression-free survival were immature. Grade 3 or higher drug-related adverse events occurred in 31% of the patients. The most common adverse event was diarrhea (in 84 to 91%), with diarrhea of grade 3 or higher occurring in 5 to 23%. Treatment was discontinued by 3% of the patients owing to drug-related adverse events. CONCLUSIONS: -mutant NSCLC. Diarrhea was the most common adverse event. (Funded by Bayer; SOHO-01 ClinicalTrials.gov number, NCT05099172.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 870
Self-citationHER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S.-W., Planchard, D., Ahn, M.-J., Smit, E. F., de Langen, A. J., Pérol, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01361 · Cited by 328
Self-citationRobichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Self-citationZhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00297 · Cited by 205
Self-citationRiudavets, M., Sullivan, I., Abdayem, P., & Planchard, D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100260 · Cited by 196
Dziadziuszko, R., Smit, E. F., Dafni, U., Wolf, J., Wasąg, B., Biernat, W., Finn, S. P., Kammler, R., Tsourti, Z., Rabaglio, M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.017 · Cited by 160
Le, X., Cornelissen, R., Garassino, M., Clarke, J. M., Tchekmedyian, N., Goldman, J. W., Leu, S.-Y., Bhat, G., Lebel, F., Heymach, J. V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01323 · Cited by 160
Self-citationCho, B. C., Ahn, M.-J., Kang, J. H., Soo, R. A., Reungwetwattana, T., Yang, J. C.-H., Cicin, I., Kim, D.-W., Wu, Y.-L., Lu, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00515 · Cited by 153
Reckamp, K. L., Giaccone, G., Camidge, D. R., Gadgeel, S. M., Khuri, F. R., Engelman, J. A., Koczywas, M., Rajan, A., Campbell, A. K., Gernhardt, D., et al. (2014) · Cancer · doi:10.1002/cncr.28561 · Cited by 144
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 139
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503704 · Cited by 118
Self-citationTargeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review
Zhao, J., & Xia, Y. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00333 · Cited by 112
Self-citationThe force of HER2 – A druggable target in NSCLC?
Jebbink, M., Langen, A. J. D., Boelens, M. C., Monkhorst, K., & Smit, E. F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101996 · Cited by 87
Gray, J. E., Ahn, M., Oxnard, G. R., Shepherd, F. A., Imamura, F., Cheng, Y., Okamoto, I., Cho, B. C., Lin, M., Wu, Y.-L. L. C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3146 · Cited by 81
Cornelissen, R., Prelaj, A., Sun, S. B., Baik, C. S., Wollner, M., Haura, E. B., Mamdani, H. M., Riess, J. W., Cappuzzo, F., Garassino, M. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.016 · Cited by 68
Self-citationManagement of HER2 alterations in non-small cell lung cancer – The past, present, and future
Nützinger, J., Lee, J. B., Low, J. L., Chia, P. L., Wijaya, S. T., Cho, B. C., Lim, S. M., & Soo, R. A. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107385 · Cited by 59
Li, Z., Wang, Y., Sun, Y., Wang, L., Li, X., Sun, L., He, Z., Yang, H., Wang, Y., Wang, Q., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00012-9 · Cited by 57
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
Hong, L., Patel, S., Drusbosky, L. M., Xiong, Y., Chen, R., Geng, R., Heeke, S., Nilsson, M., Wu, J., Heymach, J. V., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00720-9 · Cited by 55
Self-citationHan, B., Zhou, C., Zheng, W., Wu, L., Ma, Z., Wang, H., Yu, X., Ding, G., Ma, D., Nie, L., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.033 · Cited by 53
Self-citationSoo, R. A., Martini, J.-F., van der Wekken, A. J., Teraoka, S., Ferrara, R., Shaw, A. T., Shepard, D., Calella, A. M., Polli, A., Toffalorio, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.021 · Cited by 52
Self-citationBrazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 40
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Siegel, F., Siegel, S., Kotýnková, K., Uzunbas, G. K., Korr, D., Tomono, H., Andersen, S., Denney, D. R., Berger, M., Schulze, V., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0605 · Cited by 37
Self-citationAndrews, H. S., Zariffa, N. M.-D., Nishimura, K. K., Choi, S. H., Deng, S., Eisele, M., Espenschied, C. R., Goren, E., Guha, M., Hong, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3612 · Cited by 30
Janne, P. A., Kobayashi, K., Robichaux, J. P., Lee, C. K., Sugawara, S., Yang, T., Kim, T. M., Yanagitani, N., Kim, S., Markovets, A. A., et al. (2024) · Cancer Research · doi:10.1158/1538-7445.am2024-ct017 · Cited by 29
Self-citationSiegel, F., Siegel, S., Graham, K., Karsli-Uzunbas, G., Korr, D., Schroeder, J., Boemer, U., Hillig, R. C., Mortier, J., Niehues, M., et al. (2022) · European Journal of Cancer · doi:10.1016/s0959-8049(22)00827-9 · Cited by 17
Loong, H. H.-F., Daniele, G., Yang, T.-Y., Leal, T. A. B., Goto, K., Shinno, Y., Nishino, K., Sakamoto, T., Felip, E., Ruffinelli, J. C., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.2409 · Cited by 6
Self-citation
Cited by
Puri, S., Leighl, N. B., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02822 · Cited by 46
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Heymach, J. V., Yamamoto, N., Girard, N., Ruiter, G., Smit, E. F., Planchard, D., Nadal, E., Wu, Y.-L., Zugazagoitia, J., Tu, H., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2516969 · Cited by 23
Self-citationNitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications
Chetna, J., Mishra, S., Potuganti, G. R., Cardoza, S., & Velma, G. R. (2026) · RSC Advances · doi:10.1039/d6ra00737f · Cited by 18
Tiz, D. B., D’Alì, M., Iraci, N., Santi, C., & Sancineto, L. (2026) · Biomolecules · doi:10.3390/biom16030381 · Cited by 15
Stockhammer, P., Zarif, T. E., Schillo, J. L., Li, F., Goldberg, S. B., Politi, K. A., & Grant, M. J. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103708 · Cited by 5
Metadata
- Authors
- Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., Shinno, Y., Daniele, G., Yang, T.-Y., Kim, H. R., Ruiter, G., Zhao, J., Novello, S., Miao, L., Jänne, P. A., Goto, K., Rüttinger, D., Descamps, T., Brase, J. C., Bao, W., Li, R., Brega, N., Grassi, P., Girard, N., & Tan, D. S.-W.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Seoul National University (KR)
- Chinese University of Hong Kong (HK)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- National University of Singapore (SG)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sir Run Run Shaw Hospital (CN)
- Shanghai Jiao Tong University (CN)
- Wuhan Union Hospital (CN)
- Central South University (CN)
- National Cancer Center Hospital (JP)
- Agostino Gemelli University Polyclinic (IT)
- Taichung Veterans General Hospital (TW)
- Yonsei University (KR)
- The Netherlands Cancer Institute (NL)
- Peking University Cancer Hospital (CN)
- Ospedale San Luigi Gonzaga (IT)
- Nanjing Drum Tower Hospital (CN)
- Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute, Boston
- National Cancer Center Hospital East, Kashiwa, Japan
- Bayer (Germany) (DE)
- Bayer (United Kingdom) (GB)
- Bayer (Switzerland) (CH)
- Bayer (United States) (US)
- Bayer (Italy) (IT)
- Institut Curie (FR)
- ORCID
- Le, Xiuning
- Kim, Tae Min
- Loong, Herbert H.
- Prelaj, Arsela
- Goh, Boon Cher
- Li, Lin
- Lu, Shun
- Dong, Xiaorong
- Wu, Lin
- Shinno, Yuki
- Daniele, Gennaro
- Kim, Hye Ryun
- Ruiter, Gerrina
- Zhao, Jun
- Novello, Silvia
- Miao, Liyun
- Rüttinger, Dominik
- Descamps, Tine
- Brase, Jan Christoph
- Li, Rui
- Brega, Nicoletta
- Grassi, Paolo
- Girard, Nicolas
- Tan, Daniel Shao-Weng
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-11-06
- Volume
- 393
- Issue
- 18
- Pages
- 1819-1832
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4415295860
- Cited by
- 70
- References
- 34
- Citations by year
- 2026: 65 · 2025: 5
- FWCI
- 45.69
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- HER2-mutant non-small cell lung cancer, HER2 tyrosine kinase inhibitor, HER2-targeted therapy, antibody-drug conjugates, objective response rate, progression-free survival, diarrhea adverse event, advanced non-small cell lung cancer, oral tyrosine kinase inhibitor, previously treated patients, treatment-naive patients, duration of response, treatment discontinuation
- MeSH terms
- Progression-Free Survival, Tyrosine Kinase Inhibitors, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Diarrhea, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Time Factors, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.